These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 33150806)

  • 1. Variables associated with self-reported anxiety and depression symptoms in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.
    Shi D; Li Z; Li Y; Jiang Q
    Leuk Lymphoma; 2021 Mar; 62(3):640-648. PubMed ID: 33150806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
    Jiang Q; Wang HB; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with chronic myeloid leukemia and coronavirus disease 2019 in the Omicron era.
    Qi F; Bao M; Gao H; Zhang X; Zhao S; Wang C; Li W; Jiang Q
    Ann Hematol; 2023 Oct; 102(10):2707-2716. PubMed ID: 37578540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia.
    Sogawa R; Kimura S; Yakabe R; Mizokami Y; Tasaki M; Sueoka-Aragane N; Narisawa Y; Kimura S
    Int J Clin Oncol; 2018 Oct; 23(5):974-979. PubMed ID: 29651584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.
    Jiang Q; Wang H; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2619-2630. PubMed ID: 28894944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia.
    Jiang Q; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2018 Apr; 144(4):735-741. PubMed ID: 29380058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China.
    Jiang Q; Gale RP
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1549-55. PubMed ID: 27085530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
    Flynn KE; Myers JM; D'Souza A; Schiffer CA; Thompson JE; Atallah E
    Oncologist; 2019 Sep; 24(9):1253-1258. PubMed ID: 30944185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia.
    Jiang Q; Liu ZC; Zhang SX; Gale RP
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1539-47. PubMed ID: 27085529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
    Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
    Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between Carnitine Deficiency and Tyrosine Kinase Inhibitor Use in Patients with Chronic Myeloid Leukemia.
    Iriyama N; Miura K; Uchino Y; Takahashi H; Nakagawa M; Iizuka K; Hamada T; Koike T; Kurihara K; Nakayama T; Takei M; Hatta Y; Nakamura H
    Chemotherapy; 2022; 67(2):96-101. PubMed ID: 34839292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors.
    Ren X; Qin Y; Huang X; Zuo L; Jiang Q
    Ann Hematol; 2019 Jul; 98(7):1627-1640. PubMed ID: 31089794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution.
    Iino M; Yamamoto T; Sakamoto Y
    Hematology; 2019 Dec; 24(1):355-361. PubMed ID: 30880635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
    Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
    J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
    Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
    Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower tumor burden is associated with better cognitive function in patients with chronic phase chronic myeloid leukemia.
    Li Z; Peng L; Li Y; Zhang J; Jiang Q
    Leuk Lymphoma; 2022 Oct; 63(10):2352-2363. PubMed ID: 35543618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?
    Eskazan AE; Ozmen D
    Expert Rev Hematol; 2017 Jul; 10(7):583-586. PubMed ID: 28586242
    [No Abstract]   [Full Text] [Related]  

  • 20. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
    Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
    Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.